Retatrutide Dosage: What the Trials Used

Retatrutide dosage data in the public domain comes entirely from sponsored clinical trials. The compound is still investigational and carries no approved prescribing information. Understanding what those trials actually tested, and at what pace doses were escalated, is the most accurate starting point for anyone researching this triple-receptor agonist.

What Is Retatrutide?

Retatrutide (LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. Unlike semaglutide or tirzepatide, it acts on three receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). The additional glucagon receptor activity is theorized to increase basal energy expenditure on top of the appetite suppression seen with GLP-1 agonists, though it also introduces a distinct safety and tolerability profile that is still being characterized.

It is not FDA-approved. No regulatory body has cleared it for obesity, type 2 diabetes, or any other condition as of mid-2026. Phase 3 trials are ongoing.

The Phase 2 Trial: Design and Retatrutide Dosage Arms

The foundational human data comes from a 48-week, randomized, double-blind, placebo-controlled Phase 2 trial published in The New England Journal of Medicine in 2023. Participants were adults with a BMI of 27 or above, without type 2 diabetes.

The trial tested six active dose arms plus placebo, all administered as once-weekly subcutaneous injections:

The 12 mg/week dose arms produced the largest body weight reductions: approximately 24% mean body weight loss at 48 weeks in the high-dose cohort. Lower dose arms produced more modest but still meaningful results.

Titration Was Mandatory, Not Optional

One of the clearest takeaways from the trial design is that slow titration was built into every arm. Doses were never started at the maintenance level. The stepwise escalation was intended to improve gastrointestinal tolerability, the same strategy used with tirzepatide and semaglutide.

The slowest 12 mg arm took roughly six months of weekly injections to reach the maintenance dose. The faster 12 mg arm reached it in about three months but was associated with a higher rate of GI adverse events.

Slow, structured titration was a core feature of every retatrutide trial arm, not an afterthought.

Side Effects by Dose Level

Gastrointestinal events were the dominant tolerability concern across all active arms:

• Nausea was the most frequently reported side effect, occurring in a majority of participants on higher doses
• Vomiting and diarrhea were also common, particularly during dose escalation phases
• Constipation appeared at meaningful rates in some arms
• Higher doses and faster titration schedules were consistently associated with more frequent GI events
• A small number of participants discontinued due to adverse events, with the highest discontinuation rates in the faster high-dose arm

The trial also monitored cardiovascular parameters, liver enzymes, and bone markers, given retatrutide's glucagon receptor activity. Findings from those assessments are part of the ongoing Phase 3 evaluation.

What the Trial Data Does Not Tell You

Trial conditions are tightly controlled environments. Participants were:

• Screened for exclusion criteria that eliminate many common comorbidities
• Monitored with regular clinical visits and lab work
• Managed by experienced research teams who could intervene on adverse events

The doses in published data were selected and escalated by investigators following a pre-specified protocol. They are not a self-dosing template. Published trial doses represent what was studied under supervised conditions, not a validated starting point for unsupervised use.

There is also no published data on retatrutide in populations with kidney disease, significant cardiovascular history, or other conditions that affect drug metabolism and tolerability. Those populations would typically be screened out of early-phase trials.

How This Compares to Approved Agents

For context, here is how retatrutide's trial dosing range compares to the maintenance doses of approved agents in the same class:

The 12 mg retatrutide maintenance dose sits within the dose ranges explored for other approved agents, but direct comparisons are complicated by different receptor mechanisms, molecular structures, and trial populations.

Tracking Experimental Protocols Carefully

If you are working with a physician on an investigational protocol that includes peptide compounds, keeping an accurate dose log is important. It matters both for your own records and for communicating clearly with your care team. Redose makes it straightforward to log weekly injections, track vial inventory, and note any symptoms alongside each dose. You can download Redose here and use it alongside whatever monitoring your provider requires.

The reconstitution calculator at /calculators is also useful for any injectable peptide where you are mixing lyophilized powder with bacteriostatic water. It handles the math for concentration, volume per dose, and remaining vial doses.

Key Takeaways

• Retatrutide dosage in trials ranged from 1 mg/week up to 12 mg/week, always starting low and titrating up
• The highest reported weight loss (~24% at 48 weeks) came from the 12 mg maintenance arm with a slow titration schedule
• It is a triple agonist (GLP-1 + GIP + GCGR), which distinguishes it mechanically from approved alternatives
• It is not FDA-approved and remains under Phase 3 investigation
• GI side effects (nausea, vomiting, diarrhea) were the most common adverse events and were dose-dependent
• Trial dosing was conducted under close medical supervision and is not a framework for self-administration

The Phase 2 data for retatrutide is genuinely notable within the obesity pharmacotherapy space. But notable trial results and clinical availability are not the same thing. Until Phase 3 data matures and a regulatory review is complete, retatrutide sits firmly in the investigational category: one where patient safety still depends on the oversight structures that clinical trials provide.

This article is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.